Here’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors List

Loomis Sayles, an investment management company, released the “Growth Fund” in the second quarter of the age of 2025. A copy of the message can be downloaded here. In the second quarter, the fund returned by 18.58 % compared to 17.84 % for the Role 1000 growth index. The fund focused on the long -term stock approach in the long term for investment. In addition, please check the five best holdings of the box to know its best choices in 2025.

In the investor’s speech in the second quarter of 2025, the Lomes Siles growth fund such as Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX). Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is a biotechnology company that focuses on developing and marketing treatments to treat cystic fibrosis (CF). Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for a month of 3.98 %, has lost 16.21 % of its value over the past 52 weeks. On September 02, 2025, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) shares were closed at $ 401.00 per share, with a marketing of a market of 102,813 billion dollars.

Loomis Sayles Growth Fund is following the following regarding Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in the investor’s speech in the second quarter of 2025:

“Vertex Pharmaceuticals is compact (NASDAQ: VRTX), founded in 1989, is a global biological pharmaceutical company with deep experience in protein, genetic sciences and focus on specialized markets. The company is the leading company in creating treatments for patients with cystic fibrosis (CF), with five currently approved CF treatments, and the company builds its capabilities to treat relevant diseases that raise its basic experience in biology and medical chemistry.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is not included in our list that includes 30 popular stocks between hedge boxes. According to our database, 53 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) at the end of the second quarter, which was 60 in the previous quarter. Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) achieved 2.96 billion dollars in the second quarter, which represents 12 % growth compared to Q2 2024. While we admit that the capabilities of the drugs integrated more and carry a lower risk. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.